Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 3A, row1, col3
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 3A, row2, col3
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 3A, row3, col3
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 5D, row2, col2
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 5D, row1, col2
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 3. supp1 A
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 3. supp1 B
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 3. supp1 C
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 5 supp1, C
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|
|
Fig. 5 supp1, C
Chang LS et al. (2020)
|
Xtr WT + ptprk MO
NF 10.5 (in situ hybridization)
|
|
|